Results 131 to 140 of about 115,651 (262)

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Unlocking Selenium Chemical Space via a Programmable Synthesis Platform Bearing Cannabinoid Receptor Recognition Motifs. [PDF]

J Am Chem Soc
Iyer MR, Bhattacharjee P, Dutta S, Lobe MMM, Volesky PD, Godlewski G, Puhl HL, Hassan SA.   +7 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Alcohol and Stress Together Can Lead to Long-Term, Dementia-Like Deleterious Effects in the Brain. [PDF]

Alcohol Clin Exp Res (Hoboken)
Sergio TO, Hopf FW.
europepmc   +1 more source

Commentary on Sun and Tang: Measurement assessment and validity in problematic smartphone use

Addiction, Volume 120, Issue 4, Page 642-644, April 2025.
Richard J. E. James, Lucy Hitcham
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Lifelong vitamin B12 monitoring after gastrectomy: A case report of subacute combined degeneration with 8-year latency in an alcoholic. [PDF]

Medicine (Baltimore)
Cho HK, Kim KL, Kim KL.
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Extensive genetic interactions (epistasis) linked to alcohol use disorder in a high-risk population. [PDF]

Commun Biol
Listopad S, Peng Q.
europepmc   +1 more source

Alcohol [PDF]

Occupational Medicine, 2010
openaire   +2 more sources